Increased concentrations of neopterin in plasma, ascites and ovarian cyst fluid in malignant tumours compared with benign ovarian tumours

Anticancer Research

Volumn 16, Issue 5 B, 1996, Pages 3189-3192

  Hæger, Magnus ^a   Swahn, Marie ^a   Hahlin, Mats ^a   Horvath, György ^a   Bengtsson, Anders ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Benign ovarian tumours; Neopterin; Ovarian cysts; Ovarian malignant tumours

Indexed keywords

NEOPTERIN;

ADULT; AGED; ARTICLE; ASCITES FLUID; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYST FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; OVARY CANCER; OVARY TUMOR; PLASMA; PRIORITY JOURNAL; TUMOR VOLUME;

AGED; ASCITES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN CYSTS; OVARIAN NEOPLASMS;

EID: 0029799303     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reihnegger G, Swetley P, Troppmair J, Wachter H: Immune response-associated production of neopterin: Release from macrophages primarily under control of interferon-gamma. J Exp Med 160: 310-316, 1984.
2. Duchs DS, Bowers DS, Woolf JH, Nichol CA: Biopterin cofactor biosynthesis: GTP-cyclohydrolase, neopterin and biopterin in tissue and body fluid of mammalian species. Life Sci 35: 1895-1901, 1984.
3. Reibnegger G, Hetzel H, Fuchs D, Fuith L, Hausen A, Werner E, Wachter H: Clinical significance of neopterin for prognosis and follow up in ovarian cancer. Cancer Res 47: 4977-4981, 1987.
4. Hausen A, Fuchs D, Grunewald K, Huber H, Konig K, Wachter H: Urinary neopterin as a marker for haematological neoplasias. Clin Chim Acta 117: 297-305, 1981.
5. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H, Huber H: Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 51: 6250-6253, 1991.
6. Bichler A, Fuchs D, Hausen A, Hetzel H, Reibnegger G, Wachter H: Measurement of urinary neopterin in normal pregnant and nonpregnant women and in women with benign and malignant genital tract neoplasms. Arch Gynecol 233: 121-130, 1983.
7. Gadducci A, Ferdeghini M, Malagnino G, Prontera C, Fanucchi A, Annicchiarico C, Bianchi R, Fioretti P, Facchini V: Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gynecol Oncol 52: 386-391, 1994.
8. Marth C, Weger A, Muller-Holzner E, Zeimet AG, Moncayo-Naveda H, Daxenbichler G, Reibnegger G, Fuchs D, Wachter H, Dapunt O: The prognostic value of nuclear roundness and neopterin in ovarian cancer. Eur J Cancer 29A: 1863-1868, 1993.
9. Werner ER, Bichler A, Daxenbichler G, Fuchs D, Fuith LC, Hausen A, Hetzel H, Reibnegger G, Wachter H: Determination of neopterin in serum and urine. Clin Chem 33: 62-66, 1987.
10. Granberg S: Relationship of the macroscopic appearrance to the histologic diagnosis of ovarian tumors. Clin Obstet Gynecol 36: 363-374, 1993.
11. Schwartz PE: The role of tumour markers in the preoperative diagnosis of ovarian cysts. Clin Obstet Gynecol 36: 384-94, 1993.
12. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER: Neopterin as a marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 27: 81-141, 1989.
13. Reibnegger G, Bichler A, Dapunt O, Fuchs D, Fuith L, Hausen A, Hetzel H, Lutz H, Werner E, Wachter H: Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 46: 950-955, 1986.